anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a swine transmissible gastroenteritis nucleic acid vaccine and an immuno-enhancer and a preparation method of the vaccine. The swine transmissible gastroenteritis nucleic acid vaccine is shown as a sequence table SEQ ID No. 1. The sequence of the immuno-enhancer for the swine transmissible gastroenteritis nucleic acid vaccine is shown as a sequence table SEQ ID No. 2. Immunization is implemented by adopting the nucleic acid vaccine, the nucleic acid vaccine is simple to prepare, easy to store and transport, low in cost and suitable for large-scale production, and the safety and stability of the vaccine are ensured. The main antigen site of an immunogen is TGEV-S1 (transmissible gastroenteritis virtus-S1), so that the nucleic acid vaccine is more specific. Moreover, pIL12 is used as the immuno-enhancer, so that the immune level of CD4 and CD8 of the nucleic acid vaccine are improved, the titer of antibodies is improved, meanwhile, the duration of the antibodies is also prolonged and the immune effect of the TGEV-S1 nucleic acid vaccine is also improved.
Participants will be paired with a patient navigator. The patient navigator will contact participants: 1) Within 7 days of randomization; 2) At least once every 3 months up to 12 months; 3) As needed to follow-up on tasks identified in previous visits; and 4) As initiated by the participant. Contacts will occur during in-person clinic visits (prioritized for first encounter, if possible), or over video, telephone, SMS, and/or emails. The navigator will tailor the topics addressed during these interactions according to the needs of the participant and compile a care plan with input from the patient, family, and clinicians. In addition, to assess intervention fidelity, patient navigators will document all participant contacts on standardized forms, including topics addressed, services and coordination provided, written care plan provided, and concurrent resources/interventions accessed (e.g., social worker, funding/housing applications, support from community organizations).
Diabetes mellitus complicated with depression (DD) is a prevalent psychosomatic disorder. It is characterized by severe cognitive impairment, and associated with high rates of disability and mortality. Although conventional treatment options are available, the efficacy of these regimens in managing DD remains limited. Molecular hydrogen (H2), a selective hydroxyl radical scavenger, has shown therapeutic potential in the treatment of various systemic diseases. This study aims to investigate the therapeutic effects of H2 on DD. A DD mouse model was established through intraperitoneal injection of streptozotocin (STZ, 150 mg/kg) and lipopolysaccharide (LPS, 0.5 mg/kg). Following the induction of DD, the mice were treated with H2/O2 (66.7 %/33.3 %)inhalation for 7 days. Behavioral assessments were conducted by standard behavioral tests, and the levels of inflammatory cytokines in peripheral blood serum and hippocampal tissue were measured using enzyme-linked immunosorbent assay (ELISA). Furthermore, magnetic resonance imaging (MRI) scans and immunofluorescence staining of the hippocampus were performed to evaluate hippocampal structural integrity. The results demonstrated that inhalation of H2/O2 (66.7 %/33.3 %) significantly ameliorated depressive behaviors and symptoms in DD mice, reversed hippocampal volume reduction, decreased inflammatory cytokine levels in peripheral blood serum and hippocampal tissue, and inhibited the activation of A1 astrocytes in the hippocampus. Our study suggests that H2/O2 (66.7 %/33.3 %) inhalation therapy may offer a promising treatment strategy for DD and its associated symptoms.
This is a multi-centre, two-arm blinded feasibility clinical trial with an embedded qualitative study. Following baseline assessment, participants will be randomized (using minimization) to either: active vs. sham version of computerised Spatial Inattention Grasping Home-based Therapy (c-SIGHT). Randomization and group allocation will be managed and run by Norwich Clinical Trials Unit (independent from research team and outcome assessors). Participants, carers, outcome assessors, clinical care team and research team will be blinded to participant group allocation. Participants allocated to the active intervention c-SIGHT group will be required to lift and balance three wooden rods of different lengths. Those in the attentional control c-SIGHT group will use the same equipment, but will be required to lift the rods from one end only and not attempt to balance them (an attentional control). During the first training session a therapist (independent from the outcome assessors) will set-up the equipment and train the participant to self-administer the relevant version of c-SIGHT independently (i.e., without the presence of a therapist). Following this training session, participants will self-administer the training for 10 consecutive days (thirty-minute sessions 2 times a day - 'Training phase'). On the last day of the training (day 10) the therapist will return to participant's homes to complete a monitoring visit and collect equipment. To monitor adherence and therapy compliance the therapist will collect photos and videos of the first and last session of the training. A blinded assessor will collect outcome assessments at the end of the training phase (T1) and at one-month post-training (T2). The post-training (T1) data collection visit will also include one-to-one semi-structured interviews with stroke survivor participants and their carers (qualitative study).
Two randomized, active controlled trials of cIAI were performed. A double-blind trial was conducted primarily in North America to compare the efficacy of sequential IV/PO moxifloxacin 400 mg QD for 5 to 14 days to IV/piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of patients with cIAI, including peritonitis, abscesses, appendicitis with perforation, and bowel perforation. This study enrolled 681 patients, 379 of which were considered clinically evaluable. A second open-label international study compared moxifloxacin 400 mg QD for 5 to 14 days to IV ceftriaxone plus IV metronidazole followed by PO amoxicillin/clavulanic acid in the treatment of patients with cIAI. This study enrolled 595 patients, 511 of which were considered clinically evaluable. The clinically evaluable population consisted of subjects with a surgically confirmed complicated infection, at least 5 days of treatment and a 25 to 50 day follow-up assessment for patients at the Test of Cure visit. The overall clinical success rates in the clinically evaluable patients are shown in Table 15.
Vitamins are obtained from micro-organism fermentation broth residues or fish solubles by contacting their aqueous solutions with an activated earth or a water-miscible C1-3 alcohol or ketone, or a phenolic compound or activated carbon when in this latter case the vitamins are eluted therefrom by a mixture of a base, water and a C1-3 alcohol or ketone, or combinations of such processes.  Hot dimethyl formamide may be used to extract the vitamins from dry concentrates obtained as above, or from dry fish solubles or solid fermentation residues or to the solutions treated as above, or combinations thereof. The vitamins, in the original solution or after concentration can be separated into two active fractions by contacting their aqueous solutions with a cationexchange resin.ALSO:Growth-stimulating factors are obtained from micro-organism fermentation broth residues or fish solubles by contacting their aqueous solutions with an activated earth or a water-miscible alcohol or ketone having 1-3 carbon atoms.  In modifications, the solution is contacted with activated carbon and the factor eluted therefrom with a mixture of a base, water and an alcohol having 1-3 carbon atoms, or the adsorption on carbon followed by elution may be applied to concentrates obtained from contacting with activated earths or C1-3 alcohol or ketone or a combination of both.  Dry concentrates of the factor may be extracted with hot dimethylformamide, or such extraction may be applied directly to dry fish solubles or solid fermentation residues, or to the solutions contacted with activated earths or C1-3 alcohols or ketones, or to solutions contacted with activated carbon and subsequent eluation, or to combinations thereof.  Phenolic compounds may be used to extract the factors, either directly on the original solutions or after some concentration of the factors has been obtained.  The factors in the original solution or after concentration can be separated into two active fractions by contacting their aqueous solutions with a cation-exchange resin. The factors are added to food for animals.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of CIPRO and other antibacterial drugs, CIPRO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with CIPRO may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. 

As with other drugs, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance.
This study will employ design-based research models (Laurel, 2003) to the executive-functioning training game GroundsKeeper by CogCubed; we will assess the quality of digital designs for learning (Barab \& Squire, 2004) using established qualitative data collection to analyze game play and player reaction over a three week period of time. We will assess the participants for their ability to stay engaged in play by observing their engagement in the game, time played, frequency of play, and the ability to complete a session over the course of three weeks while in school.
The treatment lasts 15 days with 45 sessions of cTBS at a rate of 3 sessions per day. The session lasts 40 seconds and consists of 3 pulses at 50Hz repeated every 200 milliseconds (5Hz) to reach a total of 600 pulses, with a 15 minute break between sessions. The application of cTBS will be performed on the left temporo-parietal junction.
PURPOSE: To obtain a massaging agent containing albumen in highly preservable state and capable of improving the beautifying effect by compounding a specific vitamin to a system composed mainly of natural salt and containing albumen. CONSTITUTION: This massaging agent is produced by adding albumen and honey to natural salt and adding vitamin E to the mixture. The vitamin E is preferably added together with a vegetable oil such as olive oil or safflower oil. The stains in the pores and sweat-glands of the skin are removed by the osmotic pressure action of the natural salt. The albumen promotes the gelatinizing action together with honey. Vitamin E is active to prevent the oxidation of albumen and directly absorbed through the skin. The compounding ratios of the components are e.g. 870g of natural salt, 13.5g of powdery albumin, 66.5g of water, 50g of honey, 150mg of vitamin E and about 150mg of olive oil.
FIELD: medicine. SUBSTANCE: method is based upon application of two hemocarboperfusions by using ozonized sorbent at 5-7-day-long interval between procedures. That causes labile glycemia with gradual decrease of blood sugar level to the sixth day. Then course injection of dissolved ozone into blood is conducted at 0.0002-0.3 mg/kg body weight once per 3-15 days for at least 4-6 seances. EFFECT: increased sugar-reducing result, decreased diabetic complications as angiopathy, retinopathy and nephropathy. 1 dwg, 5 tbl
In recent years, the movement to promote the legalization of medical cannabis has grown in the United States and now 29 States and the District of Columbia have provisions that allow for the use of cannabis for medical reasons. Irrespective of the specific reasons for seeking medical cannabis, adults who have been evaluated for medical cannabis certification report significant sleep-related problems as well as frequent use of cannabis to address their sleep problems. Cannabis use for sleep is a key potential target for interventions given that prior research has found that, among individuals with cannabis use disorders, poor sleep is a barrier to sustained remission from cannabis use. Cognitive Behavioral Therapy (CBT) for insomnia is highly effective in individuals with insomnia comorbid with other health conditions, including substance use disorders; however, existing efficacy trials have not specifically evaluated its benefit in those who use cannabis for insomnia. The impact of CBT for insomnia on either sleep or cannabis use in medical cannabis users is, therefore, unknown. The objectives of this project are to adapt and tailor a telephone-delivered CBT for insomnia for adults who use medical cannabis (CBTi-CB) and to evaluate the acceptability and feasibility of this intervention. Qualitative and quantitative data will be collected to refine an existing CBTi-CB protocol and conduct a pilot test of the modified intervention in adults who use medical cannabis. Adults seeking certification for medical cannabis will be approached while waiting for their appointment and screened for insomnia as well as cannabis use for sleep. After initial qualitative interviews and beta testing, eligible participants (N = 60) will be randomized to CBTi-CB or Sleep Hygiene Education (SHE) control condition, delivered over the telephone. Participants will provide self-report data on sleep/insomnia, functioning and cannabis use and objective data on sleep quality will be measured by actigraphy. The study will evaluate changes in self-reported and objectively measured sleep, functioning and frequency/quantity of cannabis use during treatment and over the course of 18-weeks post-baseline. Completion of the study aims will provide all of the elements required for a future fully-powered randomized trial of the longer-term efficacy of CBTi-CB among those with medical cannabis. This line of research would be the first to evaluate a highly effective sleep-focused intervention and determine the effects on sleep-related and non-sleep-related cannabis use in a non-treatment seeking population.
Cardiac complications in patients who have undergone allogeneic hematopoietic stem cell transplantation (HSCT) have been well documented. Most commonly patients present with congestive heart failure and/or pericarditis after receiving high-dose cyclophosphamide, total body irradiation (TBI) or other intensive conditioning / preparative regimens prior to the allogeneic transplant. The majority of the data in the medical literature suggests that the rate of serious cardiac events appears to be relatively low at approximately 5% or less. Recently, there appears to have been a cluster of patient cases (approximately 15) of significant cardiomyopathy in patients who have received an allogeneic HSCT at the NIH Clinical Center over the past year. These cases have been consulted on by the Cardiology consult service and have included both NCI and NHLBI protocol patients. This cluster of cases has prompted concern that the incidence of cardiac toxicity recently seen at the NIH Clinical Center is not consistent with the reported incidence of significant cardiac toxicity in the medical literature.

The proposed retrospective chart review is intended to further define the incidence of cardiac toxicity, primarily focusing on cardiomyopathy. The project is an initial step to consolidate the data from both the NCI and NHLBI transplant programs and clarify the documented cardiac toxicities, the incidence, and the demographics of the patient populations. We also plan to document the presence or absence of a variety of known and suspected risk factors for cardiotoxicity. This analysis will only be preliminary but will potentially lead to more formal prospective studies on cardiotoxicity related to allogeneic HSCT.
In this arm, patients will have at least 2 visits with the participants primary care doctor. Before each visit, participants will complete a patient activation survey. Results of the survey will be shared with the primary care doctor and entered into the medical record so that the Diabetes Prevention Patient Activation Clinical Decision Support Tool can be used by the participants doctor during the visit to discuss lifestyle management.
FIELD: dairy industry. SUBSTANCE: invention relates to isolation of biologically active milk proteins, among them pancreatic ribonuclease A, angiogenin and lysozyme. Ultrafiltrate as a dairy raw is concentrated firstly by 10-12 times by means of reverse osmosis through membrane with pore size 1 000-5 000 Da under pressure 0.4-0.7 MPa and temperature 4-10 C. Then method involves purification of protein solution from lactose and mineral substances by addition of potassium-phosphate buffer, pH is 6.7-7.0, by diafiltration. Prepared protein concentrate is sterilized by microfiltration through membrane with pore size 0.10-0.45 mcm under pressure 0.2-0.7 MPa and temperature 4-10 o C. Invention ensures to enhance biological activity of protein concentrate due to enrichment with RNAase, angiogenin and lysozyme preparing from dairy ultrafiltrate using membrane processes. EFFECT: improved preparing method. 1 dwg
Subjects will be randomized to receive either danirixin BID or placebo BID treatment along with standard care of treatment for 52 weeks. Subjects completing Part A and meeting the eligibility criteria for Part B could also be randomized in Part B.
PURPOSE: To rationalize a cost as stages are simple without the need for catalysts and without residues by executing a silylation treatment with a silazane compd. having perfluoroalkyl groups. CONSTITUTION: The perfluoroalkyl silazane which has (A) hexagonal boron nitride (NB) powder having an average grain size of 0.5 to 30μm, high purity of >=90wt.% and crystallization of >=500Åin the LC value measured by the method of Carbon Material 117 committee of the Japan Society for Promotion of Scientific Research, (B) a least one perfluoroalkyl groups expressed by -CH2 CH2 CF3 ,-CH2 CH2 (CF2 )7 CF3 , -C8 F17 , etc., and silazane bond (tri-Si-NH-) and is not particularly restricted in the kinds of other functional groups, the presence or absence of the functional groups for connecting the perfluoroalkyl groups and silicon atoms and the kinds thereof in the case of the presence, the degree of polymn. of the silazane, is used as the raw material.  A component B of 0.1 to 50 pts.wt. is dispersed into an org. solvent and is mixed with 100 pts.wt. component A and thereafter the mixture is dried.
* have kidney disease. You may need a lower dose of levetiracetam.
  * are pregnant or planning to become pregnant. It is not known if levetiracetam can harm your unborn baby.  
You may also join the North American Antiepileptic Drug Pregnancy Registry by calling (888) 233-2334 (toll free).
  * are breast feeding. Levetiracetam can pass into your milk and may harm your baby.You should choose to either take levetiracetam or breast feed, but not both.



Tell your healthcare provider about all the medicines you take, including prescription, nonprescription, vitamins, and herbal supplements.

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist each time you get a new medicine.
The development of serotonin syndrome has been reported with the use of methylene blue class products. Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs). Opioids and dextromethorphan may increase the risk of developing serotonin syndrome. Some of the reported cases were fatal. Symptoms associated with serotonin syndrome may include the following combination of signs and symptoms: mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, and hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, and incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Avoid concomitant use of PROVAYBLUE with serotonergic drugs and opioids.

Patients treated with PROVAYBLUE should be monitored for the emergence of serotonin syndrome. If symptoms of serotonin syndrome occur, discontinue use of PROVAYBLUE, and initiate supportive treatment. Inform patients of the increased risk of serotonin syndrome and advise them to not to take serotonergic drugs within 72 hours after the last dose of PROVAYBLUE [see Drug Interactions (7), Patient Counseling Information (17)].
Clinical experience with RISPERDAL® in patients with certain concomitant systemic illnesses is limited. Patients with Parkinson's Disease or Dementia with Lewy Bodies who receive antipsychotics, including RISPERDAL®, are reported to have an increased sensitivity to antipsychotic medications. Manifestations of this increased sensitivity have been reported to include confusion, obtundation, postural instability with frequent falls, extrapyramidal symptoms, and clinical features consistent with the neuroleptic malignant syndrome.

Caution is advisable in using RISPERDAL® in patients with diseases or conditions that could affect metabolism or hemodynamic responses. RISPERDAL® has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were excluded from clinical studies during the product's premarket testing.

Increased plasma concentrations of risperidone and 9-hydroxyrisperidone occur in patients with severe renal impairment (creatinine clearance <30 mL/min/1.73 m2), and an increase in the free fraction of risperidone is seen in patients with severe hepatic impairment. A lower starting dose should be used in such patients [see Dosage and Administration (2.4)].
PURPOSE:A safe agent for alleviating pain, administrable for a long period, comprising 24,25-dihydrocholecalciferol as an active ingredient. CONSTITUTION:24,25-Dihydroxycholecalciferol (this substance for short), preferably 24R,25-dihydroxycholecalciferol is used as an agent for alleviating pain in tumor, especially in stomach cancer, metastasis of tumor to the stomach. The problem of clinical symptoms in malignant tumor is pain, and, this substance is found to have pain alleviating action on tumor. This substance is extremely safe substance. It is administered orally or parenterally. A dose is preferably 0.5-10,000mug/day.
Galinpepimut-S (GPS) vaccinations are started 12-22 days following autologous stem cell transplantation (ASCT). GPS and Montanide (in a 1 mL emulsion) are administered subcutaneously (s.c.) Q2W on weeks 0, 2, 4, 6, 8, and 10. GM-CSF (70 μg) are administered s.c. one to two days before and on the day of GPS/Montanide administration. Participants whose disease has not progressed and who are clinically stable (no active infection with fevers and no cardiovascular/respiratory compromise) may receive up to 6 additional monthly vaccinations. The use of post-ASCT maintenance therapy is allowed starting 3 months after ASCT.